Cardiotoxic interaction of metabolites from a prodrug segment cilexetil (cyclohexyloxy-carbonyloxy-ethyl) with digoxin in the canine failing heart

Pharmacological Research

Volumn 46, Issue 4, 2002, Pages 301-310

  Okunishi, Hideki ^a   Shimoura, Keiko ^a   Wang, Dang Qiao ^a   Kakizoe, Eiichi ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Arrhythmia; Cyclohexanediol; Digoxin; Heart failure; Torsade de pointes

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; CANDESARTAN HEXETIL; CARDIAC GLYCOSIDE; CEFAZOLIN; CEFOTIAM HEXETIL; CILEXETIL; CYCLOHEXANE DERIVATIVE; CYCLOHEXANEDIOL; CYCLOHEXANOL; DIGOSIN; DIGOXIN; DRUG METABOLITE; ESTER; PRODRUG; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIOVENTRICULAR BLOCK; AVOIDANCE BEHAVIOR; BRADYCARDIA; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG MECHANISM; HEART; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE CONTRACTION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; ISCHEMIC HEART DISEASE; ISOMER; NONHUMAN; PRIORITY JOURNAL; TACHYCARDIA; TORSADE DES POINTES;

EID: 0036426352     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043661802001743     Document Type: Article

References (25)

1. Davydov L, Cheng JW. Tenecteplase: A review. Clin Ther 2001; 23: 982-97.
2. Bachmann KA, Ghosh R. The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Curr Drug Metab 2001; 2: 299-314.
3. Fang J, McKay G, Hubbard JW, Hawes EM, Midha KK. Dose staggering as a strategy to reduce drug-drug interactions due to reversible enzyme inhibition between orally administered drugs with high first pass effect: A computer simulation study. Biopharm Drug Dispos 2000; 21: 249-59.
4. Tanayama S, Yoshida K, Mitani M, Tsukamoto T, Torii H. Metabolic fate of cefotiam hexetil, a new oral cephalosporin antibiotic, in rats, mice, and dogs [abstract in English]. Chemotherapy 1988; 36(Suppl 6): 146-66.
5. Maier H, Attallah M, Weidauer H. Efficacy and safety of cefotiam hexetil in the treatment of ear, nose and throat infections. Arzneimittelforschung 1992; 42: 980-2.
6. Okada Y, Asai M, Yasumatsu M, Takeda M, Miura T. Gas chromatographic determination of metabolites of the ester side-chain of cefotiam hexetil (2HCl) in human plasma and urine [abstract in English]. Chemotherapy 1988; 36(Suppl 6): 126-37.
7. Kito G, Wada T, Yoshimura H, Saji Y. General pharmacological studies on cefotiam hexetil (2HCl) [abstract in English]. Chemotherapy 1988; 36(Suppl 6): 167-79.
8. Tanayama S, Yoshida K, Mitani M, Tsukamoto T, Torii H. Metabolic fate of cefotiam, a new oral cephalosporin antibiotic, in rats, mice, and dogs [abstract in English]. Chemotherapy 1988; 36(Suppl 6): 146-66.
9. Tateno M, Sugiyama M, Ebi O. Phase I clinical study on cefotiam hexetil [abstract in English]. Chemotherapy 1988; 36(Suppl 6): 180-202.
10. Ong CN, Sia GL, Chia SE, Phoon WH, Tan KT. Determination of cyclohexanol in urine and its use in environmental monitoring of cyclohexanone exposure. J Anal Toxicol 1991; 15: 13-6.
11. Millis GA, Walker V. Urinary excretion of cyclohexanediol, a metabolite of the solvent cyclohexanone, by infants in a special care unit. Clin Chem 1990; 36: 870-4.
12. Jackson EK. Renin and angiotensin. In: Hardman JG, Limbird LE, Gilman AG, eds. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001: 809-41.
13. Weir MR, Weber MA, Neutel JM, Vendetti J, Michelson EL, Wang RY. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: A clinical experience trial. ACTION Study Investigators. Am J Hypertens 2001; 14: 567-72.
14. Spinale FG, Zellner JL, Tomita M, Crawford FA, Michael MR. Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circ Res 1991; 69: 1058-67.
15. Elsner D, Riegger GAJ. Characteristics and clinical relevance of animal models of heart failure. Curr Opin Cardiol 1995; 10: 235-59.
16. Greenberg BH. Role of angiotensin receptor blockers in heart failure not yet RESOLVD. Circulation 1999; 100: 1032-4.
17. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study. Circulation 2000; 101: 378-84.
18. Komamura K, Shannon RP, Ihara T, Shen YT, Mirsky I, Bishop SP, Vatner SF. Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol 1993; 265(Heart Circ Physiol 34): H1119-31.
19. Nielsen CU, Andersen R, Brodin B, Frokjaer S, Steffansen B. Model prodrugs for the intestinal oligopeptide transporter: Model drug release in aqueous solution and in various biological media. J Control Release 2001; 73: 21-30.
20. Miyauchi M, Endo R, Hisaoka M, Yasuda H, Kawamoto I. Synthesis and structure-activity relationships of a novel oral carbapenem, CS-834. J Antibiot 1997; 50: 429-39.
21. Ooi H, Colucci WS. Pharmacological treatment of heart failure. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 10th Edn. New York: McGraw-Hill, 2001: 901-32.
22. Akera T, Brown BS. Cardiovascular toxicology of cardiotonic drugs and chemicals. In: Stee EWVS, ed. Cardiovascular Toxicology. 1st Edn. New York: Raven Press, 1982: 109-34.
23. Tamargo J. Drug-induced torsade de pointes: From molecular biology to bedside. Jpn J Pharmacol 2000; 83: 1-19.
24. Roden DM. Antiarrhythmic drugs. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 10th edn. New York: McGrwa-Hill, 2001: 933-70.
25. Delpón E, Valenzuelan C, Tamargo J. Blockade of cardiac potassium and other channels by antihistamines. Drug Saf 1999; 21(Suppl 1): 11-8.